- Home
- EBTC vs XNCR Comparison
EBTC vs XNCR Comparison
Compare EBTC & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EBTC
- XNCR
- Stock Information
- Founded
- EBTC 1989
- XNCR 1997
- Country
- EBTC United States
- XNCR United States
- Employees
- EBTC N/A
- XNCR N/A
- Industry
- EBTC Major Banks
- XNCR Biotechnology: Pharmaceutical Preparations
- Sector
- EBTC Finance
- XNCR Health Care
- Exchange
- EBTC Nasdaq
- XNCR Nasdaq
- Market Cap
- EBTC 506.0M
- XNCR 579.3M
- IPO Year
- EBTC 2005
- XNCR 2013
- Fundamental
- Price
- EBTC $38.55
- XNCR $8.00
- Analyst Decision
- EBTC
- XNCR Buy
- Analyst Count
- EBTC 0
- XNCR 8
- Target Price
- EBTC N/A
- XNCR $29.29
- AVG Volume (30 Days)
- EBTC 23.6K
- XNCR 1.1M
- Earning Date
- EBTC 07-22-2025
- XNCR 05-07-2025
- Dividend Yield
- EBTC 2.59%
- XNCR N/A
- EPS Growth
- EBTC 11.95
- XNCR N/A
- EPS
- EBTC 3.27
- XNCR N/A
- Revenue
- EBTC $172,242,000.00
- XNCR $127,228,000.00
- Revenue This Year
- EBTC N/A
- XNCR N/A
- Revenue Next Year
- EBTC N/A
- XNCR $27.37
- P/E Ratio
- EBTC $11.79
- XNCR N/A
- Revenue Growth
- EBTC 7.98
- XNCR N/A
- 52 Week Low
- EBTC $22.60
- XNCR $7.16
- 52 Week High
- EBTC $44.41
- XNCR $27.24
- Technical
- Relative Strength Index (RSI)
- EBTC 49.08
- XNCR 41.88
- Support Level
- EBTC $38.45
- XNCR $7.47
- Resistance Level
- EBTC $39.11
- XNCR $7.99
- Average True Range (ATR)
- EBTC 0.68
- XNCR 0.48
- MACD
- EBTC -0.19
- XNCR 0.05
- Stochastic Oscillator
- EBTC 29.78
- XNCR 38.54
About EBTC Enterprise Bancorp Inc
Enterprise Bancorp Inc is a holding company engaged in the business of gathering deposits from the general public and investing in loans and investment securities. Through the Bank and its subsidiaries, the company offers a range of commercial, residential, and consumer loan products, deposit products, and cash management services, as well as wealth management and wealth services.
About XNCR Xencor Inc.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.